Recombinant Human Endothelial-Monocyte Activating Polypeptide II

Catalog No: #AP60038

Package Size: #AP60038-1 5ug #AP60038-2 100ug #AP60038-3 500ug

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	Recombinant Human Endothelial-Monocyte Activating Polypeptide II
Host Species	Escherichia coli.
Purification	> 98 % by SDS-PAGE and HPLC analyses.
Other Names	SCYE1, EMAP-2, Small Inducible Cytokine Subfamily E Member 1
Calculated MW	Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Target Sequence	SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Images



Background

Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.